特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
390811

バイオ医薬品の世界市場 - タイプ、用途、地域別 - 成長、トレンド、および予測

Biopharmaceuticals Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
バイオ医薬品の世界市場 - タイプ、用途、地域別 - 成長、トレンド、および予測
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のバイオ医薬品市場は、2018年から2023年にかけて、8.5%のCAGRで拡大し、2023年には3,411億6,000万米ドルに達すると予測されています。

当レポートでは、バイオ医薬品の世界市場を調査し、市場の概要、タイプ、治療用途、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析

  • 市場の成長要因
  • 市場の阻害要因
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 製品タイプ別
    • モノクローナル抗体
    • 組換成長因子
    • 精製タンパク質
    • 組換えタンパク質
    • 組換えホルモン
    • 合成免疫調節剤
    • ワクチン
  • 治療用途別
    • 腫瘍
    • 炎症性感染症
    • 自己免疫疾患
    • 代謝性疾患
    • ホルモン疾患
    • 疾患予防
    • 心血管疾患
    • 神経疾患
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 南米
    • 中東・アフリカ

第8章 競合情勢

  • M&A分析
  • 合意、提携、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co.
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Roche Holding AG
  • Others

第10章 市場の将来展望

目次
Product Code: 51323

The global biopharmaceuticals market is found witnessing a CAGR of 7.32%. The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. Also, the huge demand of biopharmaceutical is facilitated by an accelerating focus in research and related investment.

The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. About 70% of the potential medicines in development represent novel approaches to addressing diseases in areas, such as neurology, cancer, diabetes, and immunology. Biopharmaceuticals have thus seen to reduce the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

In addition, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent both the side-effects associated with some small-molecule therapeutics and invasive surgical treatments. However, high cost, along with the difficulty of the development of a biopharmaceutical drug, is one growth limiting factor.

Key Market Trends

Monoclonal Antibodies is Expected to Hold a High Market Share During the Forecasted Period

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. This application has improved the market scope for this particular enzyme in the recent years.

North America Dominates the Market and Expected to do the Same in the Forecast Period

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. The United States has shown an incredible growth over the past several years. The country has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.

The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Acceptance for Biopharmaceuticals
    • 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
    • 4.2.3 Huge Market Demand
  • 4.3 Market Restraints
    • 4.3.1 High-end Manufacturing Requirements
    • 4.3.2 Complicated and Cumbersome Regulatory Requirements

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Monoclonal Antibodies
      • 5.1.1.1 Anti Cancer Monoclonal Antibodies
      • 5.1.1.2 Anti-inflammatory Monoclonal Antibodies
      • 5.1.1.3 Other Monoclonal Antibodies
    • 5.1.2 Recombinant Growth Factors
      • 5.1.2.1 Erythropoietin
      • 5.1.2.2 Granulocyte Colony Stimulating Factor
    • 5.1.3 Purified Proteins
      • 5.1.3.1 Leukemia Inhibitory Factor (LIF)
      • 5.1.3.2 P53 Protein
      • 5.1.3.3 P38 Protein
      • 5.1.3.4 Other Purified Proteins
    • 5.1.4 Recombinant Proteins
      • 5.1.4.1 Serum Albumin
      • 5.1.4.2 Amyloid Protein
      • 5.1.4.3 Defensin
      • 5.1.4.4 Transferrin
    • 5.1.5 Recombinant Hormones
      • 5.1.5.1 Recombinant Human Growth Hormones
      • 5.1.5.2 Recombinant Insulin
      • 5.1.5.3 Other Recombinant Hormones
    • 5.1.6 Vaccines
      • 5.1.6.1 Recombinant Vaccines
      • 5.1.6.1.1 Cancer Vaccines
      • 5.1.6.1.2 Malaria Vaccines
      • 5.1.6.1.3 Ebola Vaccine
      • 5.1.6.1.4 Hepatitis B Vaccine
      • 5.1.6.1.5 Tetanus Vaccine
      • 5.1.6.1.6 Diptheria Vaccine
      • 5.1.6.1.7 Cholera Vaccine
      • 5.1.6.1.8 Other Recombinant Vaccines
      • 5.1.6.2 Conventional Vaccines
      • 5.1.6.2.1 Polio Vaccine
      • 5.1.6.2.2 Pox Vaccine
      • 5.1.6.2.3 Other Conventional Vaccines
    • 5.1.7 Recombinant Enzymes
      • 5.1.7.1 Enterokinase
      • 5.1.7.2 Cyclase
      • 5.1.7.3 Caspase
      • 5.1.7.4 Cathepsin
    • 5.1.8 Cell and Gene Therapies
      • 5.1.8.1 Allogeneic Products
      • 5.1.8.2 Autologous Products
      • 5.1.8.3 Acellular Products
    • 5.1.9 Synthetic Immunomodulators
      • 5.1.9.1 Cytokines, Interferones, Interleukins
    • 5.1.10 Other Product Types
      • 5.1.10.1 Blood Factors
      • 5.1.10.2 Other Product Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Oncology
    • 5.2.2 Inflammatory and Infectious Diseases
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Metabolic Disorders
    • 5.2.5 Hormonal Disorders
    • 5.2.6 Cardiovascular Diseases
    • 5.2.7 Neurological Diseases
    • 5.2.8 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 India
      • 5.3.3.2 China
      • 5.3.3.3 Japan
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Eli Lily & Co.
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Novo Nordisk Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 F. Hoffmann-La Roche AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.